News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

Study finds patients may not benefit from recommended longer periods of DAPT

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents. Photo courtesy of Siemens Healthineers

Photo courtesy of Siemens Healthineers

November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months among patients treated with second-generation drug-eluting stents (DES).

Findings were reported at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF), Oct. 29-Nov. 2 in Denver.

International guidelines recommend 12 months of DAPT for STEMI patients after primary peructaneous coronary intervention (PCI) with DES due to ongoing atherothrombotic risk. While longer duration DAPT therapy reduces the risk of ischemic events, it is also associated with a higher risk of major bleeding that can sometimes be fatal. Second-generation DES have a lower stent thrombosis risk than their predecessors, questioning the need for an extended duration of DAPT.

DAPT STEMI was a prospective, randomized trial designed to evaluate whether six months of DAPT was non-inferior to 12 months in event-free patients at six-month follow-up after primary PCI. The study enrolled 1,100 STEMI patients who underwent primary PCI with a second-generation zotarolimus-eluting stent. Those who were event-free at six months and agreed to continue with the study (N=870) were randomized to single antiplatelet therapy (SAPT, N=433) or DAPT (N=437). Baseline and procedural characteristics were similar in both arms.

The study’s primary endpoint was a patient-oriented composite of all-cause mortality, any myocardial infarction, any revascularization, stroke or thrombolysis in myocardial infarction (TIMI) major bleeding at 18-month follow-up after randomization (i.e. two years after primary PCI). The primary endpoint occurred in 4.8 percent of the SAPT group versus 6.6 percent for the DAPT group {HR 0.73; 95% CI (0.41-1.27); P= 0.26; Pnon-inferiority=0.004}. The incidences of the individual components of the primary endpoint were as follows:

  • Mortality: 0.7 percent in SAPT vs. 1.4 percent in DAPT {HR 0.51; 95% CI (0.13-2.02); P=0.33};
  • Myocardial infarction: 1.8 percent vs. 1.8 percent {HR 1.02; 95% CI (0.38-2.71); P=0.97;
  • Revascularization: 3 percent vs. 3.9 percent {HR 0.87; 95% CI (0.42-1.83); P=0.72;
  • Stroke: 0.7 percent vs. 0.7 percent {HR 1.02; 95% CI (0.21-5.03); P=0.99; and
  • TIMI major bleeding: 0.2 percent vs. 0.5 percent {HR 0.51; 95% CI (0.05-5.57); P=0.58.

“For the first time in the modern DES era, this trial indicates that STEMI patients, similar to stable angina patients, may not benefit from prolonged DAPT therapy beyond six months as currently recommended,” said Elvin Kedhi, M.D., Ph.D., head of the Interventional Cardiology and Clinical Research and Innovation at Isala Hartcentrum in Zwolle, The Netherlands. “This sets the stage for further dedicated research on this important topic.”

The DAPT STEMI trial was funded by Maasstad Cardiovascular Research. Kedhi reported receiving consulting fees/honoraria or institutional grants from Medtronic, Abbott, Meril and OrbusNeich.

Watch a VIDEO interview on tthis study

For more information: www.tctconference.com

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 

 

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Overlay Init